|Bid||3.29 x 900|
|Ask||3.77 x 800|
|Day's Range||3.3700 - 3.7300|
|52 Week Range||1.1500 - 7.3500|
|Beta (3Y Monthly)||4.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.01|
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system, announced its registrational pathway, updated clinical development plans and the estimated market opportunity for the Company’s lead candidate AFM13 – a first-in-class innate cell engager – at its Research & Development Day in New York City. Affimed plans to initiate a Phase 2 study evaluating the safety and efficacy of AFM13 as monotherapy in relapsed or refractory peripheral T cell lymphoma (PTCL) and transformed mycosis fungoides (TMF), a subset of cutaneous T cell lymphoma (CTCL) in the first half of 2019.
- Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with.
Heidelberg, Germany, November 28, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer.
Market players have felt trapped so when the opportunity arises to escape they have been taking advantage. This morning the indices have traded straight up from the opening bell and breadth is running extremely strong with about 5300 gainers to 1328 decliners. The dilemma of market action like this is that most individual stocks still have very poor charts.
In 2011 Adi Hoess was appointed CEO of Affimed NV (NASDAQ:AFMD). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Heidelberg, Germany, November 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted.
Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of -29.41% and 18.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Established strategic collaboration agreement with Genentech for NK cell engager-based immunotherapeutics: Received $96 million in upfront and committed funding, may be.
Heidelberg, Germany, November 1, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted.
Heidelberg, Germany, October 31, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer.
Affimed (AFMD) puts two phase I studies evaluating its CD19/CD3-targeting T cell engager, AFM11, on clinical hold due to one death and two life-threatening events.
Here are some of the companies with shares expected to trade actively in Tuesday’s session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 8) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
Check out the companies making headlines after the bell: Tesla TSLA shares rose 1 percent in after-hours trading after investment firm Macquarie gave the automaker an 'outperform' rating and a price target of $430.
Affimed NV shares plunged late Monday following a brief halt as the biotech drug developer put two clinical trials on hold after one study participant died. Affimed shares dropped 28% after hours, following an 11% gain to close at $4.63 Monday. The company halted two Phase 1, or early-stage, clinical stage for its cancer treatment AFM11 after one patient died and two others experienced "life-threatening events" in the high-dose group. Phase 1 studies are used to gauge the safety of an experimental drug. The studies were testing the drug in patients with types of non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK and T cells), today announced that it has placed AFM11 (CD19/CD3-targeting T cell engager) on clinical hold, and has notified the global health authorities of its decision. AFM11 is being evaluated in two Phase 1 clinical studies for the treatment of patients with relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL).
HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal. Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months.